Changeflow GovPing Government & Legislation FDA Acknowledgment Letter to Event Oval
Routine Notice Added Final

FDA Acknowledgment Letter to Event Oval

Favicon for www.regulations.gov Regulations.gov Final Notices
Detected March 25th, 2026
Email

Summary

The U.S. Food and Drug Administration (FDA) has issued an acknowledgment letter to Event Oval regarding a submission. The letter, authored by CDRH, confirms receipt of the submission but contains no substantive details or regulatory requirements.

What changed

This document is an acknowledgment letter from the FDA's Center for Devices and Radiological Health (CDRH) to Event Oval, confirming receipt of a submission. The content of the submission itself is not detailed, and the letter serves primarily as administrative confirmation.

As this is a routine acknowledgment, there are no immediate compliance actions required for regulated entities. Compliance officers should note this as administrative correspondence related to a specific submission, but it does not impose new obligations or require any changes to current practices.

Source document (simplified)

Content

There are no documents available to view or download

Attachments 1

Acknowledgment Letter from FDA DMB to Event Oval

More Information
- Author(s) CDRH
Download

Classification

Agency
GSA
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
FDA-2026-V-0281-0002
Docket
FDA-2026-V-0281

Who this affects

Applies to
Medical device makers
Industry sector
3345 Medical Device Manufacturing
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Compliance
Topics
Medical Devices

Get Government & Legislation alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when Regulations.gov Final Notices publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.